BioCentury
ARTICLE | Company News

Angiotech paclitaxel-eluting graft deal

March 24, 2005 3:24 AM UTC

Angiotech (TSX:ANP; ANPI) granted CABG Medical ( CABG) an exclusive license to use paclitaxel drug-eluting technology in CABG's Holly Graft System. The Holly Graft System is a polytetrafluoroethylene (ePTFE) graft that can be attached to the coronary arteries to avoid the need to harvest vessels from the chest, legs or arms for use in the bypass procedure. The device will use a drug combination that includes paclitaxel to reduce the risk of blockage. ...